Yasasever V, Dinçer M, Camlica H, Duranyildiz D, Dalay N
Department of Basic Oncology, I.U., Oncology Institute, Istanbul, Turkey.
Eur J Gynaecol Oncol. 1997;18(5):397-9.
In this study the value of PHI serum measurements in breast cancer as an index of metastases was investigated. Serum CA 15-3 and CEA tumor marker and gamma-glutamyltranspeptidase (gamma-GT) levels were also determined in groups of patients with established distant metastases or in patients on follow-up with no evidence of disease. Fifty-one female breast cancer patients were included in the study. The mean values for each parameter were higher when metastases were present. However, the difference was mostly not meaningful. The only significant difference was observed for CA 15-3. Our data do not support the usefulness of the PHI assay for early detection of the metastases in breast cancer.
在本研究中，对乳腺癌患者血清PHI测量值作为转移指标的价值进行了研究。还对已发生远处转移的患者组或随访中无疾病证据的患者测定了血清CA 15-3、癌胚抗原（CEA）肿瘤标志物和γ-谷氨酰转肽酶（γ-GT）水平。51名女性乳腺癌患者纳入研究。存在转移时各参数的平均值较高。然而，差异大多无意义。仅CA 15-3观察到显著差异。我们的数据不支持PHI检测用于早期发现乳腺癌转移的有效性。
